GM-CSF-adjuvanted DNA/MVA vaccine: Phase I start

Next month, GeoVax will begin a U.S. Phase I trial to evaluate its GM-CSF-adjuvanted DNA/MVA vaccine. The trial is sponsored by the NIH's National Institute of Allergy and Infectious Diseases (NIAID) ...